Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Current Treatment Options in First-line FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, FACP, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Experts on follicular lymphoma discuss first-line treatment options available for patients.
EP. 2: ASH 2023 Updates on Frontline Therapies in FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, FACP, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.
EP. 3: Current Treatment Options in Second-line FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, FACP, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Experts on follicular lymphoma discuss second-line treatment options available for patients.
EP. 4: CAR T-cells as Third-line and Beyond Therapy for FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, FACP, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
EP. 5: Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
EP. 6: Tazemetostat as Third-line and Beyond Therapy for FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
EP. 7: Zanubrutinib as Third-Line and Beyond Therapy for FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
EP. 8: Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
EP. 9: Choosing CAR T-cells as Third-line and Beyond Therapy for FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
EP. 10: Sequencing Immunotherapy in the Third-line and Beyond Setting for FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
EP. 11: Unmet Needs in Treating Relapsed/Refractory FL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.
EP. 12: Current Treatment Options in First-Line MCL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Experts on mantle cell lymphoma discuss first-line treatment options available for patients.
EP. 13: ASH 2023 Updates on Frontline Therapies in MCL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.
EP. 14: Current Treatment Options in Second-line MCL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Experts on mantle cell lymphoma discuss second-line treatment options available for patients.
EP. 15: Current Treatment Options in Third-line MCL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
EP. 16: Sequencing Therapies in the Third-Line and Beyond Setting for MCL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
EP. 17: Future Directions and Unmet Needs in Relapsed/Refractory MCL By Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
